Islatravir

So just something to be aware of just because that mutation is somewhat common.

But again, the Doraverine, Islatravir is something that you could consider in a patient who you're switching due to renal concerns.

Okay, shall we move on and talk about a second case, Dr. Moring-Pierre? Yes,

sounds good.

And now the science.

The headline treatment story out of Rio was once weekly oral therapy, Two phase three trials, Iceland 1 and Iceland 2, tested a single tablet containing islatravir 2 milligrams and lenacapravir 300 milligrams, taken once a week.

Islatravir is a nucleoside reverse transcriptase translocation inhibitor.

Lenacapravir is a capsid inhibitor.

Different mechanisms, non-overlapping resistance, and long half-lives, which is exactly why they pair well for weekly dosing.

First, these are switch studies.

Everyone enrolled was already suppressed, already adherent with no history of virologic failure and no hepatitis B co-infection.

And that last exclusion matters because neither Islatravir nor Lenacapavir treats hep B.